IDEXX Laboratories, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BLRT07
IDXX
IDEXX Laboratories, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Diagnostics & Research
NAME
IDEXX Laboratories, Inc.
ISIN
US45168D1046
TICKER
IDXX
MIC
XNAS
REUTERS
IDXX.OQ
BLOOMBERG
IDXX US
F&G:
65
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 13.05.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28,...
IDEXX Laboratories
Do., 01.05.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.
“IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North Am...
IDEXX Laboratories
Do., 03.04.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Individuals can access a live webcast of the con...
IDEXX Laboratories
Do., 13.02.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:
Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate an...
IDEXX Laboratories
Mo., 03.02.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.
“IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said Jay Mazelsky, President and Chief Executive Officer. "The Company is on the front end of a n...
IDEXX Laboratories
Do., 16.01.2025
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Individuals can access a live...
IDEXX Laboratories
Mo., 09.12.2024
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discre...
IDEXX Laboratories
Do., 21.11.2024
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX’s Executive Vice President, Chief F...
IDEXX Laboratories
Do., 31.10.2024
IDEXX Laboratories
US45168D1046
In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (inste...
IDEXX Laboratories
Do., 31.10.2024
IDEXX Laboratories
US45168D1046
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.
Third Quarter Results
The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% orga...
IDEXX Laboratories
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
